In some real-world studies, overall survival (OS) outcomes in patients with advanced NSCLC treated with CTx, IO, or CIT were found to be worse among patients with KRAS-mutated NSCLC with co-mutations in STK11 or KEAP1, compared with tumors with KRAS mutations alone (Table 1A). This evidence concerns the gene KRAS and non-small cell lung carcinoma.